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ABSTRACT
Objective: Heart failure (HF) continues to be a leading
cause of hospital admissions, particularly in underserved
patients. We hypothesised that providing individualised
self-management support to patients and feedback on use
of evidence-based HF therapies (EBT) to physicians could
lead to improvements in care and decrease
hospitalisations. To assess the feasibility of conducting a
larger trial testing the efficacy of this dual-level
intervention, we conducted the Congestive Heart failure
Adherence Redesign Trial Pilot (CHART-P), a proof-of-
concept, quasi-experimental, feasibility pilot study.
Setting: A large tertiary care medical centre in Chicago.
Participants: Low-income patients (<US$30 000/year)
hospitalised for exacerbation of systolic HF (ejection
fraction ≤50%) and their physicians. Twenty physicians
and 33 patients were enrolled, of whom 23 patients
completed the study.
Interventions: Physicians received HF guidelines and
periodic individualised feedback on their adherence to
EBT. Patients received HF education, support and self-
management training for diet and medication adherence
by a trained nurse through 11 interactive sessions over a
4-month period. Evaluations were conducted pre-
enrolment and 1 month postintervention completion.
Outcome measures: Feasibility was assessed by the
ability to deliver intervention to patients and physicians.
Exploratory outcomes included changes in medication and
sodium intake for patients and adherence to EBT for
physicians.
Results: Eighty-seven per cent and 82% of patients
received >80% of interventions at 1 month and by study
completion, respectively. Median sodium intake declined
(3.5 vs 2.0 g; p<0.01). There was no statistically
significant change in medication adherence based on
electronic pill cap monitoring or the Morisky Medication
Adherence Scale (MMAS); however, there was a trend
towards improved adherence based on MMAS.
All physicians received timely intervention.
Conclusions: This pilot study demonstrated that the
protocol was feasible. It provided important insights about
the need for intervention and the difficulties in treating
patients with a variety of psychosocial problems that
undercut their effective care.
INTRODUCTION
Heart failure (HF) continues to increase in
prevalence with an enormous impact on
mortality (approximately 50% at 5 years post-
diagnosis), hospitalisations and cost of care
(US$30.7 billion in 2012).1 2 The prevalence
of HF among those 18 years and older in the
USA is projected to increase by 46% in the
next 15 years, resulting in more than 8
million people with HF by 2030.2 This reality
has created a signiﬁcant and increasing
ﬁnancial burden on the healthcare system.
Although HF therapies exist with demon-
strated beneﬁts on mortality, morbidity and
quality of life,3 these therapies are being
underutilised.4 5 Racial minorities and socio-
economically disadvantaged patients have a
higher prevalence of HF and higher readmis-
sion rates,6 7 thus contributing disproportion-
ately to the HF epidemic.
There is a particular need to develop effect-
ive interventions targeting economically disad-
vantaged patients with HF.8 Results from our
previously published Heart failure Adherence
and Retention Trial (HART) suggested that
patients with an annual income <US$30 000
might beneﬁt from counselling to improve
self-management skills as a means to lower
mortality and HF hospitalisation rates.9 Since
physician adherence to evidence-based
therapy has been shown to be suboptimal,5
Strengths and limitations of this study
▪ The intervention studied is multilevel, in that it
targets physicians and patients simultaneously.
Such strategies are potentially more potent than
those with a single focus.
▪ The intervention studied provided individualised
feedback to patients and physicians.
▪ The targeted population is low-income patients
with heart failure who are disproportionally
affected by the heart failure epidemic. Few studies
have targeted this population, and our pilot study
helped us in gaining important insights into this
challenging group of patients before conducting a
larger trial.
▪ This is a pilot feasibility study performed at a
single medical centre.
▪ The sample size is small and the duration of
follow-up was short.
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providing education to physicians could offer additional
value. We hypothesised that the use of a dual-level inter-
vention strategy, intervening simultaneously on patients
and their physicians, would translate into signiﬁcantly
improved quality of care among low-income patients with
HF and improve their outcomes. To assess the feasibility of
conducting a large trial to study the efﬁcacy of this dual-
level strategy, we conducted the Congestive Heart failure
Adherence Redesign Trial (CHART) pilot study.
METHODS
The CHART pilot study was a proof-of-concept, pre–post
treatment group only design. The key objective was to
assess the feasibility and potential impact of our dual-
level intervention for low-income patients with HF and
their physicians. We would deem the intervention feas-
ible if we were able to achieve four objectives: (1) assess
patient adherence to prescribed therapies and sodium
restriction, (2) deliver the intervention to patients, (3)
assess physician adherence to evidence-based HF
therapy and (4) provide timely feedback to physicians.
Recruitment
The study targeted patients with systolic HF with self-
reported annual household income <US$30 000, as these
patients are at high risk for adverse outcomes.7 9 All partici-
pants were recruited while hospitalised at the Rush
University Medical Center in Chicago, Illinois. Patients
were identiﬁed via monitoring of hospital admission logs
and the echocardiography laboratory database. New HF
admissions with systolic dysfunction (ejection fraction
≤50% as measured by echocardiography, radionuclide ven-
triculography or radiographic contrast ventriculography)
were included. Patients having HF with preserved ejection
fraction were excluded as there are no set guidelines for
managing these patients, deeming the proposed physician-
level intervention non-feasible. Eligibility of the identiﬁed
candidates was then determined based on self-reported
income. Exclusion criteria included being a cardiac trans-
plant candidate, having severe aortic stenosis, uncontrolled
ventricular arrhythmias, B-type natriuretic peptide
<100pg/mL, severe asthma or chronic obstructive pulmon-
ary disease, major psychiatric comorbidities, alcohol or
drug addiction, haemodialysis treatment, debilitating
neurological conditions, severe arthritis, peripheral arterial
disease, or having an uncertain 12 month prognosis. Once
an eligible patient was identiﬁed, it was checked whether
their physician was on staff at the medical centre. If the
physician was on staff, their consent for study participation
was obtained. Subsequently, the patients were recruited
and consented. As this was a proof-of-concept study primar-
ily aimed at assessing feasibility, sample size calculations
were not performed.
Interventions
The dual-level intervention targeted both the patients and
physicians caring for their HF (a general practitioner or a
cardiologist). Physician-level intervention provided them
with evidence-based HF guidelines in the form of a bro-
chure summarising the 2005 American College of
Cardiology/American Heart Association (ACC/AHA)
recommendations with updates from the 2009 guidelines,
which were current at the time of our study.10 11 Physicians
also received summary reports of their patient’s medica-
tion use at baseline, 1 and 4 months, as obtained from
medical records and patient self-reports. These reports
were accompanied by standardised personal notes from
our study cardiologist ( JEC) outlining patient-speciﬁc
recommendations, such as possible medication changes,
that could optimise adherence to evidence-based therapy
as deﬁned by class I ACC/AHA recommendations. This
being a feasibility study with a short follow-up time, we
addressed only evidence-based medication classes but not
optimal medication dosing. No feedback to the personal
notes was solicited or tracked.
Patient-level intervention provided to each enrolled
patient a tailored HF self-management kit.12 The kit
included brochures featuring patient-friendly HF educa-
tion material and a variety of self-management tools
(scale, measuring bottle, educational materials and pill-
boxes). Patients were coached on use of the kit during
one-on-one contacts timed to occur 3 days post hospital
discharge, then once weekly for 1 month and every
2 weeks thereafter for another 3 months, totalling 11
intervention contacts. The patient contacts were per-
formed in person or via telephone at the patient’s dis-
cretion. These contacts were conducted by a trained
nurse who followed a problem-solving format in which
patients were encouraged to articulate barriers to their
adherence and to use a variety of self-management strat-
egies to overcome them.13 Simple metaphors were used
to educate patients about their HF. The heart was
equated to a ‘workhorse’ carrying a ‘load’ (blood and
water) throughout the body via the ‘road’ (arteries).
‘Water pills’ (diuretics) ‘lighten the load’ and ACE inhi-
bitors (ACE-I) or angiotensin receptor blockers (ARBs)
‘widen the road’, making it easier for the workhorse to
pump. The importance of adhering to prescribed medi-
cations, a low sodium diet, daily weighing, regular phys-
ical activity, smoking cessation, and regular follow-up
with providers was emphasised. Stress reduction strat-
egies were also discussed. Patient comprehension of
these components was assessed at each contact and their
knowledge reinforced whenever gaps were identiﬁed.
Outcomes, measures, and data analyses
The impact of the dual-level intervention on physician
adherence to evidence-based therapy focused speciﬁcally
on appropriate use of an ACE-I or ARB, β-blocker and
aldosterone antagonist. Data on physician adherence
were gathered by chart audit at baseline and at
5 months for each patient enrolled. Only patients who
remained in the study for the 5 month evaluation were
included in these analyses. Physician adherence with
respect to a given medication was measured using the
2 Mangla A, et al. BMJ Open 2014;4:e006542. doi:10.1136/bmjopen-2014-006542
Open Access
group.bmj.com on October 14, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
proportion of their patients who were prescribed the
medication, based on those for whom it was appropriate
according to the 2005 and 2009 ACC/AHA guidelines
and as conﬁrmed by the study cardiologist.10 11 Pre–post
change in percentage physician adherence and average
physician adherence was assessed via Student t tests or
the Wilcoxon tests, as appropriate.
Patient adherence to prescribed therapies was deter-
mined at baseline and at 5 months, using both electronic
pill cap monitoring (using the MEMS V Trackcap;
AARDEX, Zug, Switzerland) and the Morisky Medication
Adherence Scale (MMAS).14 MMAS provides a score of
0–4, with 4 indicating the highest adherence. Each
patient’s pill cap use was monitored for an ACE-I, ARB,
β-blocker or diuretic, in that order depending on which
of these drugs was prescribed. Patients were instructed to
place a month’s supply of monitored medication into
their pill cap container and use it over the ensuing
month. Patient adherence was then measured based on
the percentage of time a patient took a pill relative to the
prescribed timing. Patients were designated ‘adherent’ if
their observed adherence was ≥80%.9 13 15 The pre–post
change in per cent adherence was analysed via paired
Student t tests or the Wilcoxon tests, as appropriate. The
pre–post change in the proportion of patients designated
as ‘adherent’ (via a pill cap or MMAS) was analysed via
McNemar’s exact test. Sodium intake was determined by
a Food Frequency Questionnaire speciﬁcally designed to
assess sodium intake16 and the pre–post change was ana-
lysed via paired Student t test or the Wilcoxon test, as
appropriate.
Sensitivity analyses were conducted to account for
missing data at the 5-month data collection. The analysis
consisted of a comparison of results under three different
data replacement approaches: (1) a ‘Best Case’ scenario
in which missing values were replaced with values indicat-
ing ‘adherence’ (the maximum value, for the MMAS);
(2) a ‘Worst Case’ scenario in which missing values
were replaced with values indicating ‘non-adherence’
(minimum value for MMAS) and (3) a ‘Middle Case’
scenario in which missing values were replaced with the
last observation carried forward.
During scheduled follow-up visits, patients were asked
whether or not they had been recently hospitalised.
Data on all reported hospitalisations were collected after
obtaining proper consent. To provide a preliminary esti-
mate of the intervention’s impact on rehospitalisations,
the 30-day readmission rate among the study cohort was
compared with the year 2010’s 30-day hospital readmis-
sion rate at the site from which they were recruited
(Rush University Medical Center).
RESULTS
Between January and July 2010; 266 patients with systolic
HF were screened (ﬁgure 1); 146 met the exclusion cri-
teria; 29 were unreachable; 22 patients refused to enrol
and the physicians for 36 patients refused to participate
in the study. Data on the reasons for physicians’ refusal
were not gathered. Thirty-three patients and their 20
physicians (18 cardiologists and 2 general practitioners)
were enrolled; 23 patients (70%) fully completed the
study follow-up; 1 patient died (3%) and 5 (15%) with-
drew. Four patients (12%) were lost to follow-up after
they had received >80% of their intervention visits.
There were no clinically or statistically signiﬁcant differ-
ences in the baseline characteristics of patients who
completed the study versus those who did not.
Table 1 summarises the baseline characteristics of all
the 33 patients who were enrolled. Table 2 summarises
the outcome data for physicians and patients at study
completion. Physician adherence with respect to any
given drug class could only be evaluated in patients with
an indication for that medication at baseline and at
5 months. As a result, of the 20 physicians who were
enrolled, only 13 were evaluable for ACE-I/ARBs, 10 for
β-blockers, and 11 for aldosterone antagonists. At base-
line, 69% and 100% of physicians were appropriately pre-
scribing ACE-I/ARB and β-blockers, respectively, over all
of their patients enrolled in the study. At 5 months, this
adherence rate increased to 77% of enrolled physicians
for ACE-I/ARBs and decreased to 90% for β-blockers. For
aldosterone antagonists, physician adherence was 17% at
baseline and dropped to 0% at 5 months. These changes
in physician adherence rates were not statistically
signiﬁcant.
For the 23 patients who completed the study, self-
reported sodium intake declined by 1192 mg (p<0.01)
from baseline. Their pill cap adherence decreased as only
4 of 23 (17%) patients were adherent at study completion
versus 10 of 23 (43%) at baseline (p=0.02). However, the
proportion of patients scoring the maximum on MMAS
improved from 9 (39.1%) at baseline to 15 (65.2%) at
study completion (p=0.18).
The feasibility of the protocol for patients was assessed
as adherence to patient interventions: all patients
received at least 1 intervention visit, 87% (29/33) of
patients completed at least 4 (80%) of the protocol-
required 5 scheduled intervention visits within the ﬁrst
month and 82% (27/33) of participants completed at
least 9 (81.8%) of the protocol-required 11 intervention
visits within the 4-month intervention period. Among all
completed visits, 66% were performed in person and
the remaining by phone. Given the small sample size, it
is difﬁcult to comment on the differences in outcomes
based on whether a patient received the majority of
interventions in person versus over the phone. All physi-
cians received the study-supplied patient summary
report within 2 weeks of the data being collected from
the patient.
The 33 patients reported a total of 20 hospitalisations
during the study follow-up, for which medical records
were reviewed. The 30-day all-cause readmission rate was
15.2% (5/33), all of which were for HF exacerbation.
The 30-day all-cause readmission rate for the hospital in
2010 was 28.3% (143/505).
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Sensitivity analyses with respect to missing data at the
5-month study visit revealed that the results presented
in table 2 were fairly robust, given the size of the
sample. Almost all changes from baseline in physician
adherence continued to be non-statistically signiﬁcant
for all three medication classes under all three sensitiv-
ity analysis scenarios. The exception was observed
under the ‘Worst Case’ scenario, in which an even
deeper decrease in adherence with respect to
β-blockers was observed that achieved statistical signiﬁ-
cance (p<0.01). Sensitivity analyses with respect to
patient-drug adherence and sodium intake data pro-
duced results similar to those presented in table 2, with
the exception of an even greater decrease (that was
statistically signiﬁcant, p<0.01) in patient adherence as
measured by pill cap at 5 months under the ‘Worst
Case’ scenario and a statistically signiﬁcant (p=0.03)
increase in adherence as measured by the Morisky
score under the ‘Best Case’ scenario.
DISCUSSION
The primary purpose of this pilot study was to assess the
feasibility of a novel intervention and gain important
insights into issues that may need to be addressed in a
larger trial.17 From that perspective, our pilot study had
encouraging results. We were able to deliver the inter-
vention to both physicians and patients. All physicians
received appropriate patient-speciﬁc feedback in a
timely manner and more than 80% of patients com-
pleted at least 80% of their intervention visits. We were
able to acquire data on hospitalisations and deaths.
These ﬁndings suggest that the intervention is amenable
to implementation in a larger trial. While a pilot study is
not designed to provide deﬁnitive insights as to the
impact of an intervention, we observed a signiﬁcant
decline in sodium intake and a trend towards a lower
rate of HF hospitalisations in study patients compared
with the general hospital census. One of the exploratory
aims of our study was to assess changes in sodium
intake, as sodium restriction in patients with HF was an
area of potential intervention based on the prevailing lit-
erature at the time.18 19 In fact, sodium restriction in
patients with HF was a class I recommendation based on
the 2005 and 2009 ACC/AHA guidelines.10 11 This has
been challenged recently by studies showing adverse out-
comes in patients with HF with low daily sodium
intake.20–22 Current ACC/AHA guidelines for HF still
recommend sodium restriction, though as a Class IIa
recommendation.3
Figure 1 Flow sheet from
screening to study completion.
4 Mangla A, et al. BMJ Open 2014;4:e006542. doi:10.1136/bmjopen-2014-006542
Open Access
group.bmj.com on October 14, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Our pill cap data indicated a trend towards decreased
patient adherence postintervention while data from
MMAS indicated otherwise. Although pill cap
monitoring is an objective adherence measure, it relies
on appropriate use by the patient. MMAS, on the other
hand, is subjective but has been shown to correlate with
cardiovascular outcomes.23 This discordance between
pill cap and MMAS data may have been due to poor
acceptability of pill caps among study participants or
due to biased reporting with MMAS, as patients may
have learnt to provide favourable answers. Furthermore,
7 (30%) participants who completed the study follow-up
did not return their electronic pill caps at the study
intervention, handicapping our ability to draw infer-
ences concerning patient medication adherence and
representing a large drawback to this methodology. Use
of pill caps in low-income populations poses challenges.
Future studies should initiate measures to ensure
adequate patient education on their use and return.
Physician adherence to ACE-I/ARB and β-blockers was
high at baseline with not much room for improvement.
For aldosterone antagonists, the prescription rate was
low at baseline. Aldosterone antagonists require careful
and regular monitoring of renal function and serum
potassium levels. Such rigorous monitoring may be difﬁ-
cult in the challenging patient population that we
studied, and could account for the low adherence to a
certain extent. In a larger trial, if we can ensure timely
physician follow-up, the prescription of this class of med-
ications to appropriate patients may see a better trend.
Recruiting physicians was met with resistance, as some
physicians were unwilling to participate. Our dual inter-
vention strategy is relatively novel, and with this being a
pilot study, resistance from physicians is not surprising.
It is plausible that the physicians who refused to partici-
pate may represent a subset of providers who are not
receptive to feedback. The impact of physicians’ unwill-
ingness to participate on patients’ outcome remains
unknown. Providing feedback to physicians regarding
their adherence to evidence-based therapy is likely to be
part of healthcare delivery going forward. These have
been implemented in a variety of ways such as providing
reimbursement incentives, penalties and electronic
medical record alerts. In this trial, we chose to provide
more personalised and patient-centred feedback. The
ideal mechanism and format of most effective feedback
needs to be investigated.
Approximately 27% of the enrolled patients withdrew
or were lost to follow-up. Of these, two patients com-
pleted their interventions but did not return for the
postintervention visit; four patients refused additional
follow-up after the baseline visit. Our interactions with
these participants revealed that they were experiencing a
variety of social, psychological and emotional challenges
that limited their ability to effectively manage their HF.
Expanding the scope of the patient-level intervention to
provide stronger and more personal support may
enhance their ability to self-manage their condition.
This could be achieved by utilising community health
workers who are part of a patient’s local community and
can go directly to their homes, providing support and
Table 1 Baseline characteristics of enrolled patients
Total enrolled 33
Demographics
Age (years), mean±SD 58±13.0
Women, N (%) 21 (63.6)
African-American, N (%) 29 (87.9)
Hispanic, N (%) 3 (9.1)
Age at end of education (years), N (%)
8–11 10 (30.3)
12 13 (39.4)
13–15 9 (27.3)
17+ 1 (3.0)
Income, N (%)
US$0–US $4999 2 (6.1)
US$5000–US$9999 9 (27.3)
US$10 000–US$14 999 6 (18.2)
US$15 000–US$19 999 4 (12.1)
US$20 000–US$24 999 6 (18.2)
US$25 000–US$29 999 6 (18.2)
Medical history, N (%)
Current smoker 3 (9.1)
Past smoker 6 (18.2)
Has a pacemaker 20 (60.6)
Valvular heart disease 6 (18.2)
Hypertension 31 (93.9)
Coronary artery disease 19 (57.6)
Myocardial infarction 7 (21.2)
Stroke 4 (12.1)
Diabetes mellitus 18 (54.5)
COPD* 2 (6.3)
Asthma 8 (24.2)
Morisky Medication Adherence Scale
score of 4; median (Q1, Q3)†
3 (3, 4)
Serum Creatinine (mg/dL), mean±SD 1.5±0.8
Systolic BP (mm Hg), mean±SD 116.6±16.7
Diastolic BP (mm Hg), mean±SD 74.1±11.7
BP >130/80, N (%) 5 (15.2)
BMI (kg/m2), mean±SD* 33.4±7.7
Dietary sodium (g), mean±SD* 3.6±1.5
Patient medication adherence
Pill caps returned, N (%) 30 (90.9)
Medications measured, N (%)
▸ ACE inhibitor 19 (57.6)
▸ Angiotensin receptor blocker 9 (27.3)
▸ β-blocker 4 (12.1)
▸ Diuretic 1 (3.0)
Percentage of prescribed drugs
taken,
median (Q1, Q3)
77.3 (55.4, 88.9)
Participants ≥80% adherent‡,
N (%)
13 (43.3)
*N=32.
†Score of 4 on Morisky Medication Adherence Scale indicates full
medication adherence.
‡N=30.
BMI, body mass index; BP, blood pressure; COPD, chronic
obstructive pulmonary disease.
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counselling in important psychosocial areas which
undercut delivery of quality medical care. This can
potentially lead to better outcomes in this challenging
patient population.
Lessons learnt
Given our experiences in the CHART pilot trial, we
implemented the following adjustments in the large
CHART (NCT01698242): (1) we decided to approach
the physicians before the patients, which streamlined the
recruitment process and guided appropriate resource
utilisation; (2) patients were screened more rigorously to
avoid early dropouts; (3) we decided to provide the
patient-level intervention at the patient’s home, rather
than at a clinic, utilising community health workers who
are members of the patient’s own community and can
cross cultural and logistical barriers encountered in deli-
vering care for low-income patients; (4) we implemented
reminders and incentives to enhance the return of the
pill cap bottles in order to ensure completeness of medi-
cation adherence data and (5) we enhanced the
physician-level intervention by providing access to online
educational modules and simplifying physician feedback
to include graphically presented adherence data.
CONCLUSION
Dual-level interventions appear to provide a promising
strategy for improving outcomes among low-income
patients with HF. Our ﬁndings indicate not only poten-
tial beneﬁts but also unique challenges in treating
patients from disadvantaged backgrounds. Attention to
psychosocial and logistical issues that undercut effective
medical care may be needed.
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‡ MMAS (0–4, where 4 indicates full adherence).
§p<0.01.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; MMAS, Morisky Medication Adherence Scale.
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